Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China

International Journal of Medical Sciences

Volumn 8, Issue 4, 2011, Pages 321-331

  Zhang, Hong ^a   Li, Qingmei ^a   Sun, Jie ^a   Wang, Chunyan ^a   Gu, Qing ^a   Feng, Xiangwei ^a   Du, Bing ^a   Wang, Wei ^a   Shi, Xiao Dong ^a   Zhang, Siqi ^a   Li, Wanyu ^a   Jiang, Yanfang ^a   Feng, Junyan ^a   He, Shumei ^a   Niu, Junqi ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Hepatitis B; Immunity; Seroepidemiologic study; Vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CHINA; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRINKING BEHAVIOR; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FEMALE; GENDER; HEALTH SURVEY; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OCCUPATION; POPULATION RESEARCH; RISK FACTOR; SEROPREVALENCE; SLEEP QUALITY; SMOKING; VACCINATION;

EID: 79958804687     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.321     Document Type: Article

References (33)

1. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;250:1118-29.
2. Qu JB, Zhang ZW, Shimbo S, et al. Urban-rural comparison of HBV and HCV infection prevalence in eastern China. Biomed Environ Sci. 2000;13:243-53.
3. Kurugöl Z, Koturoǧlu G, Akşit S, et al. Seroprevalence of hepatitis B infection in the Turkish population in Northern Cyprus. Turk J Pediatr. 2009;51:120-6.
4. Liaw YF. Management of patients with chronic hepatitis B. J Gastroenterol Hepatol. 2002;17:406-8.
5. Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology. 2009;49: s35-44.
6. Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007;12:160-7.
7. Mossong J, Putz L, Patiny S, et al. Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg. Epidemiol Infect. 2006;134:808-13.
8. Liang JH, Wang M, Liu JH, et al. [Study on the immunization coverage and effects of hepatitis B vaccine in the 20-59 years-old population in Guangzhou city.]. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31:1336-9.
9. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550-7.
10. Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis. 2009;200:39-47.
11. Zhang ZW, Shimbo S, Qu JB, et al. Hepatitis B and C virus infection among adult women in Jilin Province, China: an urban-rural comparison in prevalence of infection markers. Southeast Asian J Trop Med Public Health. 2000;31:530-6.
12. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-25.
13. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15:1356-61.
14. Zhang LP, Yang P, Li FH, et al. [Hepatitis viruses infection situation in Mianyang of the Sichuan province]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008;22:449-51.
15. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168-74.
16. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759-68.
17. Davaalkham D OT, Nymadawa P. Seroepidemiology of hepatitis B virus infection among children in Mongolia: results of a nationwide survey. Pediatrics International. 2007;49:368-74.
18. Davaalkham D, Ojima T, Nymadawa P, et al. Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol. 2004;99:2032-7.
19. Zhang H, He SM, Sun J, et al. Prevalence and etiology of abnormal liver tests in an adult population in jilin, china. Int J Med Sci. 2011;8:254-62.
20. Tsai NC, Holck PS, Wong LL, et al. Seroepidemiology of hepatitis B virus infection: analysis of mass screening in Hawaii. Hepatol Int. 2008;2:478-85.
21. Lee DH, Kim JH, Nam JJ, et al. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci. 2002;17:457-62.
22. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187-92.
23. Tawk HM, Vickery K, Bisset L, et al. The impact of hepatitis B vaccination in a Western country: recall of vaccination and serological status in Australian adults. Vaccine. 2006;24:1095-106.
24. Tswana S, Chetsanga C, Nyström L, et al. A sero-epidemiological cross-sectional study of hepatitis B virus in Zimbabwe. S Afr Med J. 1996;86:72-5.
25. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55:1-33.
26. Lee A, Cheng FF, Chan CS, et al. Sero-epidemiology and risk factors of positive hepatitis B surface antigen amongst Chinese adolescents. Asia Pac J Public Health. 2001;13:30-5.
27. Cakirbay H, Bilici M, Kavakçi O, et al. Sleep quality and immune functions in rheumatoid arthritis patients with and without major depression. Int J Neurosci. 2004;114:245-56.
28. Wood RC, MacDonald KL, White KE, et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA.1993;270:2935-9.
29. Ismay SL, Thomas S, Fellows A, et al. Post-transfusion hepatitis revisited. Med J Aust. 1995;163:74-7.
30. Datta SD, Fiore AE, Mast E, et al. Routine booster doses of hepatitis B vaccine for health care workers are not necessary. Arch Intern Med. 2000;160:3170-1.
31. Keating GM NS. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003;63:1021-51.
32. Keating GM, Noble S. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines. 2004;3:249-67.
33. Su FH, Chen JD, Cheng SH, et al. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat. 2008;15:14-9.